rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found K-ras(G13D) mutation to occur at far greater incidence in cells derived from xenografted tumors or exposed to conditions of combined hypoxia and hypoglycemia in vitro.
|
16166287 |
2005 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, G12V mutations appeared to be associated with higher rates of tumor regression than G13D mutations (p=0.012).
|
19913317 |
2010 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this analysis, use of cetuximab was associated with longer overall and progression-free survival among patients with chemotherapy-refractory colorectal cancer with p.G13D-mutated tumors than with other KRAS-mutated tumors.
|
20978259 |
2010 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, a recent report suggested that the use of cetuximab was associated with survival benefit among patients with p.G13D-mutated tumors.
|
22043994 |
2012 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Although the G13D KRAS mutation normally predicts an intermediate outcome, the aggressive tumor behavior suggests other modifying factors in rare types of colonic carcinomas.
|
22180717 |
2011 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients with KRAS wild-type tumors have a longer progression-free survival (7.30 months [95% CI, 4.48-10.12 months]; HR 0.46 [95% CI, 0.23-0.91]; P = .025) and overall survival (19.0 months [95% CI, 10.2-27.8 months]; HR 0.32 [95% CI, 0.15-0.69]; P = .004) than patients with p.G13D-mutated tumors.
|
22537608 |
2012 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The addition of cetuximab to first-line chemotherapy seems to benefit patients with KRAS G13D-mutant tumors.
|
22734028 |
2012 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients who had mCRC with the KRAS p.G13D mutation appeared to benefit more from cetuximab than patients who had tumors with KRAS codon 12 mutations.
|
22972628 |
2013 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ongoing controversies such as whether patients with KRAS G13D- (or BRAF V600-) mutated tumours can still respond to EGFR-targeted mAbs and the potential impact of inter- and intra-tumour heterogeneity on tumour sampling show that the usefulness of KRAS as a biomarker has not yet been exhausted, and that other downstream biomarkers should be considered.
|
23375249 |
2013 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Whereas, the KRAS mutation p.Gly13Asp have been detected only in MSI-H. 43.75 % of the patients harboured combined mutations in KRAS and TP53 genes and the tumor of 71.42 % of them showed TP53 overexpression.
|
24078161 |
2013 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Participating laboratories contributed information on KRAS mutation frequencies, including the G13D mutation type, as well as turnaround times for tumor block retrieval and testing.
|
24811330 |
2014 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRas G12V primary tumors showed Akt activation, and β5 integrin, vascular endothelial growth factor A (VEGFA), and Serpine-1 overexpression, whereas KRas G13D tumors showed integrin β1 and angiopoietin 2 (Angpt2) overexpression.
|
25359494 |
2015 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Mutations in primary tumors were identified in three regions; KARS (G13D) and APC (R876*) in P1-2, TP53 (A161S) in P1-3, and KRAS (G12D), PIK3CA (Q546R), and ERBB4 (T272A) in P1-4.
|
25623536 |
2015 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Prior to treatment there were significant metabolic differences between SW48 WT and SW48-KRAS-G13D tumors, reflecting higher oxidative stress and glucose utilization in the KRAS-G13D tumors.
|
26709701 |
2015 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate whether the efficacy of anti-EGFR mAbs for mCRC differs between tumours harbouring a KRAS G13D mutation (KRAS G13D) and KRAS mutations other than G13D (other KRAS MT).
|
26812186 |
2016 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
This unique trial will yield prospective information on the efficacy of cetuximab and whether this is further enhanced with chemotherapy in two distinct populations of patients with metastatic colorectal cancer: the "quadruple wild type", which may 'superselect' for tumours sensitive to EGFR-inhibition, and the rare KRAS G13D mutated tumours, which are also postulated to be sensitive to the drug.
|
27246726 |
2016 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Compared to patients with c.38G > A (rs112445441, p.G13D), patients with c.*4066delA (rs560890523) and c.38G > A (rs112445441, p.G13D) presented more aggressive tumors with highly invasive features.
|
27256640 |
2017 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
KRAS exon 2 mutation variants were associated with heterogeneous outcome compared with unmutated tumors with KRAS G12C and G13D (trend) being associated with rather poor survival.
|
27358379 |
2016 |
rs112445441
|
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway.
|
30304546 |
2019 |